Skip to main content
Log in

Sacubitril/valsartan good value for heart failure with reduced LVEF

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure

References

  1. Sandhu AT, et al. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine : 30 Aug 2016. Available from: URL: http://dx.doi.org/10.7326/M16-0057

    Google Scholar 

  2. Packer M, et al. Sacubitril-Valsartan in Heart Failure: Why Are More Physicians Not Prescribing It? Annals of Internal Medicine : 30 Aug 2016. Available from: URL: http://dx.doi.org/10.7326/M16-1932

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sacubitril/valsartan good value for heart failure with reduced LVEF. PharmacoEcon Outcomes News 761, 29 (2016). https://doi.org/10.1007/s40274-016-3369-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3369-6

Navigation